Acarix is a Swedish MedTech company marketing the CADScor®System – the innovative, non-invasive device designed to support a reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway.
We are committed to bringing about a change in the early warning and assessment of cardiac and vascular diseases. Our press releases can be found below. For product images, press kits and other inquiries, please contact us.
2022 05 11
Announcement from Acarix’s annual general meeting
Announcement from Acarix's annual general meeting The annual general meeting 2022 ("AGM") of Acarix AB ("Acarix" or the "Company") was held today on 11 May 2022 in Stockholm and the following resolutions were passed by the meeting. PR_Acarix_Announcement...
2022 05 11
Acarix AB (publ) publishes Interim Report, January – March 2022
Acarix AB (publ) publishes Interim Report, January – March 2022 Increased commercial momentum and great interest in CADScor® System on the US market PR_Acarix_Q1_2022_ENG PR_Acarix_Q1_2022_SE
2022 05 06
Acarix presents at Naventus Health Care Summit 2022
Acarix presents at Naventus Health Care Summit 2022 Helen Ljungdahl Round, President and CEO of Acarix AB (publ), will present at the Naventus Health Care Summit in Stockholm on May 10, 2022. PR_Acarix Naventus HC 2022_engPR_Acarix Naventus HC 2022_sv...
2022 04 20
Acarix publishes the annual report for 2021
Acarix Annual report for 2021 Today, Wednesday April 20, Acarix is publishing its Annual Report for 2021 PR_Acarix Annual Report 2021 ENG PR_Acarix_Årsredovisning 2021 SWE
2022 04 11
Notice of Annual General Meeting in Acarix AB
Notice of Annual General Meeting in Acarix AB The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby convened to the annual general meeting to be held on Wednesday 11 May 2022 Acarix – Notice to AGM 2022 ENG Acarix – N...
2022 04 01
MAR | FDA requests supplementary information for Acarix breakthrough designation request for heart failure diagnosis
FDA requests supplementary information for Acarix breakthrough designation request for heart failure diagnosis Acarix_PR Heart failure April 1 2022 ENG Acarix_PR Heart failure April 1 2022 SWE
2022 03 11
MAR | Acarix receives strategic order for the CADScor®System in US
Acarix receives strategic order for the CADScor®System in US Acarix_first order US_ENG Acarix_first order US_SWE
2022 03 10
Acarix presents at the Redeye Artificial Intelligence Seminar 2022.
Acarix presents at the Redeye Artificial Intelligence Seminar 2022. PM_Acarix_RedeyeAI_ENG_Final. PM_Acarix_RedeyeAI_SWE_final.
2022 02 18
Acarix kapitalmarknadsdag: Uppdatering kring strategi, marknader och målsättningar
Acarix kapitalmarknadsdag: Uppdatering kring strategi, marknader och målsättningar Vid dagens kapitalmarknadsdag för Acarix ges en uppdatering avseende Bolagets strategier och målsättningar. PM Acarix CMD SWE PM Acarix CMD ENG
2022 02 17
Acarix AB (publ) publishes Year-End Report 2021
Acarix AB (publ) publishes Year-End Report 2021 PM Acarix Q4 2021 - ENG PR Acarix Q4 2021 - SE
2022 02 09
Acarix submits breakthrough designation request with FDA for heart failure diagnosis
Acarix submits breakthrough designation request with FDA for heart failure diagnosis PR Heart failure Feb 9 2022 ENG FINAL PR Heart failure Feb 9 2022 SWE FINAL
2022 02 09
Acarix AB (publ) brings forward publication of interim report for fourth quarter to February 17, 2022
Acarix AB (publ) brings forward publication of interim report for fourth quarter to February 17, 2022 AcarixPR_Reporting day_ENG AcarixPR_Reporting day_SE
2022 02 07
Acarix invites to virtual Capital Market Day
Acarix invites to virtual Capital Market Day PR_Capital Market Day_ENG PR_Kapitalmarknadsdag_SWE
2022 01 10
MAR | Acarix appoints US based Helen Ljungdahl Round as new CEO
Acarix appoints US based Helen Ljungdahl Round as new CEO PR Acarix Appoints CEO Eng PR Acarix Appoints CEO SWE
2021 12 29
Acarix carries out a directed issue of shares
Acarix carries out a directed issue of shares Acarix - Press release - carries out a directed issue of shares Acarix - Pressmeddelande - genomför riktad nyemission av aktier till garanter
2021 12 20
Acarix announce final outcome in rights issue
Acarix announce final outcome in rights issue PM_Acarix announce final outcome in rights issue PM_Acarix offentliggör slutgiltigt utfall i företrädesemission
2021 11 30
Acarix publishes prospectus in connection with rights issue of approximately SEK 79 million
Acarix publishes prospectus in connection with rights issue of approximately SEK 79 million Acarix PR Almeria Prospekt ENG Acarix PM Almeria Prospekt SWE
2021 11 23
Announcement from Acarix’s extra general meeting
Announcement from Acarix's extra general meeting Announcement EGM 23 Nov 2021 - Acarix AB>> Kommuniké EGM 23 november 2021 - Acarix AB >>
2021 11 11
MAR | Acarix AB (publ) publishes Interim Report, January – September 2021
Acarix AB (publ) publishes Interim Report, January – September 2021 PR Acarix Q3 2021 eng >> PM Acarix Q3 2021 sv >> Acarix Q3 2021 eng >> Acarix Q3 2021 sv >
2021 11 09
MAR | Acarix accelerates US market entry with Proximo Medical as commercialization partner
MAR | Acarix accelerates US market entry with Proximo Medical as commercialization partner PR Acarix Accelerates US Market eng PR Acarix Accelerates US Market swe
2021 11 08
MAR | Acarix US expansion to be a major contributor to the company’s new financial and operational goals
MAR | Acarix US expansion to be a major contributor to the company’s new financial and operational goals PR Acarix Guidance eng
2021 11 05
Acarix Notice to EGM
Acarix Notice to EGM Acarix Notice to EGM (eng) Acarix Notice to EGM (swe)
2021 11 05
MAR | Acarix Rights Issue Launch Release
MAR | Acarix Rights Issue Launch Release Rights Issue Launch Release (eng) Rights Issue Launch Release (swe)
2021 10 27
Acarix granted US CPT reimbursement code for CADScor System
Acarix granted US CPT reimbursement code for CADScor System Acarix PR CADScor ENG
2021 09 15
Acarix begins US expansion and appoints US President
Acarix begins US expansion and appoints US President Acarix_PR_US expansion_ENG >> Acarix_PR_US expansion_SWE >>
2021 09 07
New health economic study proves the value of CADScor® in coronary disease diagnostics
New health economic study proves the value of CADScor® in coronary disease diagnostics Acarix PR CADScor HEOR publication SWE Acarix PR CADScor HEOR publication ENG
2021 08 27
Initial Dan-NICAD II results presented today at ESC
Initial Dan-NICAD II results presented today at ESC PR Acarix Dan-NICAD II abstract session SWE >> PR Acarix Dan-NICAD II abstract session ENG >>
2021 08 23
Preliminary Dan-NICAD II results to be presented at ESC
Preliminary Dan-NICAD II results to be presented at ESC PM Acarix Dan-NICAD II SWE PM Acarix Dan-NICAD II ENG
2021 08 19
Acarix AB (publ) publishes Interim Report, January – June 2021
Acarix AB (publ) publishes Interim Report, January – June 2021 PR Acarix Q2 2021 eng >> PM Acarix Q2 2021 sv >> Acarix Q2 2021 eng >> Acarix Q2 2021 sv >>
2021 05 11
Acarix AB (publ) publishes Interim Report, January – March 2021
Acarix AB (publ) publishes Interim Report, January – March 2021 PM_Acarix_Interim Report_Q1 PM_Acarix_Rapport_Q1
2021 05 11
The annual general meeting 2021 (“AGM”) of Acarix AB was held today on 11 May 2021
Announcement from Acarix's annual general meeting The annual general meeting 2021 ("AGM") of Acarix AB ("Acarix" or the "Company") was held today on 11 May 2021 and the following resolutions were passed by the meeting. Due to the ongoing corona pandemic, ...
2021 04 20
Acarix publishes the annual report for 2020
Acarix Publishes the Annual Report for 2020 Today, Tuesday April 20, Acarix is publishing its Annual Report for 2020 on the company website www.acarix.com. The Annual Report is also attached to this press release. PM_Acarix_Year-End_2020 eng Acari...
2021 04 12
Notice of Annual General Meeting in Acarix AB
Notice of Annual General Meeting in Acarix AB The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby convened to theannual general meeting to be held on Tuesday 11 May 2021. Acarix - Notice to AGM 2021 ENG(401266055.3) Acarix -...
2021 04 07
Positive, long term prognostic data from the Dan-NICAD I study published in European Heart Journal- Digital Health
Positive, long term prognostic data from the Dan-NICAD Istudy published in European Heart Journal- Digital Health Acarix AB (publ) today announced the publication of the Prognostic study, a study with long term follow up on patients from the Dan-NICAD 1 p...
2021 02 18
Acarix AB publishes Year-End Report 2020 – A strong ending of an eventful year
Acarix AB (publ) publishes Year-End Report 2020A strong ending of an eventful year The fourth quarter contributed strongly to our overall performance in 2020, with the market approvalfor CADScor® from the US Food and Drug Administration (FDA) as the ou...
2021 01 13
Positive preliminary data from Acarix’s exploratory heart failure study SEISMO
Positive preliminary data from Acarix’s exploratory heart failure study SEISMO Acarix AB (publ) today announced positive preliminary data from the exploratory SEISMO study, using its modified CADScor®System on a potential heart failure application. Ac...
2020 12 09
Acarix announces the last patient included in Dan-NICAD II study
Acarix announces the last patient included in Dan-NICADII study After the inclusion of 1726 patients, Acarix announces that the last patient has been included in Dan-NICAD II, a study of noninvasive diagnostic testing in patients with suspected Coronar...
2020 11 26
FDA identifies exclusive code for the CADScor®
FDA identifies exclusive code for the CADScor®System After yesterday’s announcement and further analysis of the FDA approval,Acarix AB today announce that the company’s marketing approval of the CADScor®System in the US was granted under a new generic ...
2020 11 25
Acarix receives US market approval for the CADScor® System
Acarix receives US market approval for the CADScor® System Acarix AB (publ) today announced that the US Food and Drug Administration (FDA) has approved the company’s De Novo application for marketing approval of the CADScor®System in the US. PR_Acari...
2020 11 18
Positive results from Acarix study presented at ISPOR, a leading health economics conference
Positive results from Acarix study presented at ISPOR, a leading health economics conference Acarix AB (publ) today announced that the company’s real-life data analysis, made in co-operation with clinics in Germany and Austria, is published as a poster...
2020 11 12
Correction: Interim report 2020-01-01 to 2020-09-30
Correction: Interim report 2020-01-01 to 2020-09-30 In the interim report that Acarix submitted today, 12 November 2020, there is a minor error under theheading “Capitalization” (page 4 in the interim report) where the last sentence is to end with 2022...
2020 10 19
Acarix changes Certified Advisor to Redeye
Acarix changes Certified Advisor to Redeye Acarix AB (publ) announces today that the company has entered into anagreement with Redeye AB regarding the position as Certified Adviser.Redeye AB will take over as Certified Adviser on October 19, 2020. Aca...
2020 09 29
Acarix carries out a directed issue of shares to guarantors in conjunction with the oversubscribed rights issue
Acarix carries out a directed issue of shares to guarantors in conjunction with the oversubscribed rights issue Acarix AB (”Acarix” or the "Company") has, as previously announced, completed the rights issue ofshares amounting to approximately SEK 56 mi...
2020 09 28
Last day of trading in paid subscribed shares (Sw. BTA)
Last day of trading in paid subscribed shares (Sw. BTA) Last day of trading in subscribed paid shares ("BTA") in Acarix AB ("Acarix" or the “Company") willbe Thursday the 1 October 2020 and stop day will be Monday the 5 October 2020.In the rights issue...
2020 09 11
Acarix announce final outcome in oversubscribed rights issue
Acarix announce final outcome in oversubscribed rights issue Acarix AB ("Acarix" or the "Company") has completed the new share issue of a maximum of86,156,738 shares with preferential rights for the Company's existing shareholders, which wasresolved by...
2020 09 09
MAR | Acarix announces preliminary outcome in oversubscribed rights issue
The board of directors of Acarix AB ("Acarix" or the "Company") has, subject to the subsequent approval of an Extraordinary General Meeting, resolved to carry out a new share issue of a maximum of 86,156,738 shares with preferential rights for the Company'...
2020 09 03
Acarix publishes a supplement to the prospectus
Acarix publishes a supplement to the prospectus The board of directors of Acarix AB ("Acarix" or the "Company") has prepared a supplement to theprospectus regarding invitation to acquire shares in the approved preferential rights issue in Acarixwhich was ...
2020 09 03
Acarix progresses with the German authorities
Acarix progresses with the German authorities Acarix AB (publ) today announced that the German Ministry of Health has stated that phonocardiography for ruling out coronary artery disease has potential for general use in Germany. The German Federal Joint C...
2020 09 02
Acarix two largest shareholders transfer subscription rights free of charge –extends the subscription period
Acarix two largest shareholders transfer subscription rights free of charge –extends the subscription period he shareholders Sunstone LSV Fund II K / S and SEED Capital DK II K / S have transferred allof the subscription rights they were entitled to in...
2020 08 31
Acarix VD Per Persson presenterade på Redeye
Acarix VD Per Persson presenterade på Redeye Vid en investerarpresentation på Redeye den 25 augusti utvecklade Acarixsvd Per Persson hur han ser på bolaget och den pågåendeföreträdesemissionen. Han gav också en uppdatering kring bolagetsframsteg. Acar...
2020 08 20
Acarix publishes prospectus in connection with rights issue of approximately SEK 56 million
Acarix publishes prospectus in connectionwith rights issue of approximately SEK 56 million Acarix_PR_publication_of_prospectus (1) Acarix_PM_offentliggörande_prospekt
2020 08 07
Acarix Publishes Interim Report, January – June, 2020
Acarix AB (publ) publishes Interim Report, January – June 2020 For us and for many other companies, the pandemic and global uncertainty have caused delays in someprioritized projects. However, in combination with a dynamic capital market this has created ...
2020 07 15
MAR | Acarix decides on a guaranteed rights issue of approximately SEK 56 million
The board of directors of Acarix AB ("Acarix" or the "Company") has, subject to the subsequent approval of an Extraordinary General Meeting, resolved to carry out a new share issue of a maximum of 86,156,738 shares with preferential rights for the Company'...
2020 05 14
Announcement from Acarix’s annual general meeting 2020
The annual general meeting 2020 ("AGM") of Acarix AB was held today on 14 May 2020 and the following resolutions were passed by the meeting... Kommuniké_årsstämma_14_maj_2020_-_Acarix_(Eng) Kommuniké_årsstämma_14_maj_2020_-_Acarix_(Sve)
2020 05 14
Acarix publishes Interim Report, January – March 2020
Acarix publishes Interim Report, January – March 2020 During the quarter we have kept focus on our priorities along with managing the impact from the globalCovid-19 situation... PR_Acarix_Q1_2020 eng PM_Acarix_Q1_2020 sv
2020 05 11
Last patient included in Acarix’s exploratory heart failure study SEISMO
Last patient included in Acarix’s exploratory heart failure study, SEISMO Acarix AB (publ) today announced that the last patient has been included in the exploratory SEISMO study on a potential heart failure application. Acarix_PR_HF study 200511 ENG Ac...
2020 04 23
Acarix publishes Annual Report for 2019
Acarix publishes annual report for 2019 Malmö, April 23, 2020 Today, Thursday April 23, Acarix is publishing its Annual Report for 2019.. The Annual Report is also attached to this press release. PR_Acarix Annual Report 2019 Acarix Year-end report ...
2020 04 14
Notice of Annual General Meeting in Acarix AB
Notice of Annual General Meeting in Acarix AB The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby convened to theannual general meeting to be held on Thursday 14 May 2020, at 10.00 at Baker & McKenzieAdvokatbyrå's premises at ...
2020 03 12
Acarix receives feedback on German reimbursement submission
Acarix AB (publ) today announced that the company has received feedbackfrom the German authorities, the Federal Joint Committee, G-BA, on its submission for reimbursement of the CADScor®System in Germany. Acarix_PR_GBA_ENG Acarix_PR_GBA_SVE
2020 02 20
MAR | Acarix Year-End Report 2019
Press release MAR | Successful rights issue enables increasedfocus on strategic initiatives The fourth quarter of 2019 was eventful, and we had the opportunity to see progressin several areas. Importantly, we closed a rights issue of SEK 43 million, b...
2020 02 18
First patient enrolled in the new clinical study FILTER-SCAD targeting 2,000 patients
Acarix AB (publ) today announced the initiation of the randomized, multicenter clinical study FILTER-SCAD to examine the cost effectiveness and safety of adding the CADScor®System as a rule-out test in patients referred with symptoms suggestive of stable c...
2020 01 14
First patients with the CADScor®System in the UK
Acarix AB (publ) (ACARIX: FN Stockholm) today announced the first commercial usage of the CADScor®System in the UK. Dr Amrit Takhar and his team at Wansford and Kingscliffe Practice, nearPeterborough, UK, is the first clinic in the UK to use the unique CAD...
2019 12 16
Acarix submits FDA application
Acarix AB (publ) (ACARIX: FN Stockholm) today announced the submission of a De Novo application to the American Food and Drug Administration (FDA) for the CADScor® System in preparation of a US market entry. The company is now cautiously initiating prepara...
2019 11 14
MAR | Interim Report, January – September 2019
Acarix finalized a rights issue to finance further market expansion
2019 10 30
MAR | Acarix announce final outcome in rights issue
Press release MAR |Acarix announce final outcome in rights issue Acarix AB ("Acarix" or the "Company") has completed the new share issue of a maximum of34,541,064 shares with preferential rights for the Company's existing shareholders, which wasresolv...
2019 10 09
Trading in subscription rights and BTAs in Acarix’ rights issue will commence tomorrow
Trading in subscription rights and BTAs in Acarix' rights issue has been delayed, due to late submission of the application to Nasdaq. This situation is beyond Acarix control. Trading will commence tomorrow, October 10. All other information in the pres...
2019 10 09
The subscription period in Acarix’ rights issue commence today
The board of directors of Acarix AB ("Acarix" or the "Company") resolved on 25 September 2019, pursuant to the authorization granted by the extra general meeting on 16 August 2019, to carry out a new share issue of a maximum of 34,541,064 shares with pref...
2019 09 30
Acarix publish EU growth prospectus in connection with rights issue of up to approximately SEK 51.8 million
The board of directors of Acarix AB ("Acarix" or the "Company") resolved on 25 September 2019, pursuant to the authorization granted by the extra general meeting on 16 August 2019, to carry out a new share issue of a maximum of 34,541,064 shares with pref...
2019 09 25
MAR | Acarix carries out a rights issue of approximately SEK 51.8 million to finance an increased market expansion
The board of directors of Acarix AB ("Acarix" or the "Company") has today, pursuant to the authorization granted by the extra general meeting on 16 August 2019, resolved to carry out a new share issue of a maximum of 34,541,064 shares with preferential rig...
2019 08 16
MAR | Announcement from Acarix’s extra general meeting
MAR | Announcement from Acarix's extra general meeting The extra general meeting ("EGM") of Acarix AB ("Acarix" or the "Company") was held today on 16 August 2019 and the following resolutions were passed by the meeting. Announcement from Acarix's extra ...
2019 08 06
MAR | Interim Report January – June 2019
MAR | Interim Report January – June 2019 ”With CADScor®System we have a fantastic opportunity to revolutionize the way the healthcare system handles patients with suspected coronary artery disease, CAD. In our daily work at Acarix, we see that the need...
2019 08 05
CADScor®System – Significantly more effective than current practice
CADScor®System – Significantly more effective than current practice Acarix AB (publ) (ACARIX: FN Stockholm) today announced the publication of a meta-analysis including 2245 patients showing Acarix’s leading CADScor®System is more than three times as e...
2019 07 17
Notice of extra general meeting in Acarix AB
Notice of extra general meeting in Acarix AB The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby convened to the extra general meeting to be held on Friday 16 August 2019, at 10.00 at World Trade Center, Jungmansgatan 12 in Ma...
2019 06 27
Acarix CADScor®System included in NICE guidelines (UK)
Acarix CADScor®System included in NICE guidelines (UK) Acarix AB (publ) (ACARIX: FN Stockholm) today announced that the CADScor®System has been included as a first line investigation for ruling out suspected stable Coronary Artery Disease by the Britis...
2019 06 10
Acarix participates on the Redeye Growth Day, Monday 10 June 2019
Acarix participates on the Redeye Growth Day, Monday 10 June 2019 On Monday, June the 10th at 3.40 PM, Per Persson CEO for Acarix, will be presenting the latest activities and strategic directions for Acarix. The Growth Day meeting will take place at Haym...
2019 05 20
MAR | Announcement from Acarix’s annual general meeting May 2019
MAR | Announcement from Acarix’s annual general meeting May 2019 May 16, 2019 The annual general meeting (“AGM”) of Acarix AB (“Acarix” or the “Company”) was held today on 16 May 2019 and the following resolutions were passed by the meeting. Adoption...
2019 05 16
MAR | Interim report, January – March 2019
MAR | Interim report, January – March 2019 May 16, 2019 ”After almost a year at Acarix, I am truly inspired by the opportunities our products offer to revolutionize heart diagnosis. We participate actively in congresses and scientific conferen...
2019 04 25
MAR | Acarix publishes annual report for 2018
MAR | Acarix publishes annual report for 2018 April 25, 2019 Today, Thursday April 25, Acarix is publishing its Annual Report for 2018 on the company website www.acarix.com. The Annual Report is found here. For further information, please contact:Per...
2019 04 16
Notice of Annual General Meeting in Acarix AB
Notice of Annual General Meeting in Acarix AB April 16, 2019 The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby convened to the annual general meeting to be held on Thursday 16 May 2019, at 10.00 at Baker & McKenzie Advok...
2019 02 20
MAR | Acarix Year-End Report 2018
Press release MAR | Market dynamics favourable for CADScor®System, addressing the challenges of the global healthcare market ”After six months at Acarix, I clearly see our market evolving and a growing opportunity for our products aimed at revolut...
2019 01 15
MAR | Acarix adapts pathway for German reimbursement
MAR | Submission of new dossier by the end of February 2019 Jan 15, 2019 Acarix AB (publ) (ACARIX: FN Stockholm) today announced it will file for German reimbursementdirectly with the Federal Joint Committee (G-BA) for its CADScorSystem®. Previously,...
2018 12 17
Acarix reports first patient enrollment in new clinical investigation exploring heart failure detection
Acarix reports first patient enrollment in new clinical investigation exploring heart failure detection Dec 17, 2018 Acarix has initiated a new explorative clinical study to develop a diagnostic algorithm possibly leading to a new functionality for early...
2018 12 10
German Clinic Orders Second Acarix CADScor®System to Further Boost Patient Capacity
German Clinic Orders Second Acarix CADScor®System to Further Boost Patient Capacity Dec 10, 2018 After three months of strong results using Acarix’s CADScor®System to evaluate potential coronary artery disease, Dr Katarina Varga, who operates two clinics...
2018 11 14
MAR | Interim Report, January – September 2018
MAR | Interim Report, January – September 2018 Nov 14, 2018 ”During the quarter we proudly reported that Kristianstad Central Hospital in Sweden evaluated the CADScor®System with a positive outcome. Due to the good result the hospital´s clinical manag...
2018 11 13
MAR | Acarix (FN STO: ACARIX) today announced that the board of directors has appointed Per Persson to Chief Executive Officer
MAR | Acarix (FN STO: ACARIX) today announced that the board of directors has appointed Per Persson to Chief Executive Officer Nov 13, 2018 Per Persson comes directly from the role as Chief Commercial Officer of Acarix. Christian Lindholm, who has serv...
2018 10 24
Acarix AB enters strategic alliance with MED Management to broaden the commercial platform toward the German outpatient market
Acarix AB enters strategic alliance with MED Management to broaden the commercial platform toward the German outpatient market Oct 24, 2018 To increase awareness and knowledge of the unique rule-out technology offered by Acarix through its CADScor system...
2018 09 20
Acarix CADScor®System for early rule-out of Coronary Artery Disease (CAD) gains traction from established German users.
Acarix CADScor®System for early rule-out of Coronary Artery Disease (CAD) gains traction from established German users. Acarix AB (publ) (“Acarix”), today reported positive feedback from German users of its handheld CADScor®System for ruling out CAD. G...
2018 09 12
Acarix gains market acceptance in Austria; new customers orders CADScor®System for ruling out Coronary Artery Disease (CAD).
Acarix gains market acceptance in Austria; new customers orders CADScor®System for ruling out Coronary Artery Disease (CAD). Sep 12, 2018 New customers orders CADScor®System for ruling out Coronary Artery Disease (CAD) Acarix AB (publ) (“Acarix”) rep...
2018 09 03
Acarix Clinical Advisory Board meeting held in parallel to ESC-conference in Munich, Germany, confirms validity of its comprehensive clinical study program
Acarix Clinical Advisory Board meeting held in parallel to ESC-conference in Munich, Germany, confirms validity of its comprehensive clinical study program 3 sep, 2018 Acarix AB (publ) (“Acarix”), today reported positive feedback for the clinical stud...
2018 08 30
Swedish hospitals successfully complete Acarix CADScor®System evaluations vs. current best clinical practice for ruling out Coronary Artery Disease
Swedish hospitals successfully complete Acarix CADScor®System evaluations vs. current best clinical practice for ruling out Coronary Artery Disease 30 aug, 2018 Acarix AB (publ) (“Acarix”), today announced that two major Swedish hospitals – Kristianstad ...
2018 08 30
Acarix Clinical Advisory Board confirms validity of its comprehensive clinical study program
Acarix Clinical Advisory Board confirms validity of its comprehensive clinical study program 30 aug, 2018 Acarix AB (publ) (“Acarix”), today reported positive feedback for the clinical study program in order to validate and expand the performance of the ...
2018 08 23
Acarix presenting the CADScor®System at ESC in Munich: a revolutionary technology for early and rapid rule out of Coronary Artery Disease
Acarix presenting the CADScor®System at ESC in Munich: a revolutionary technology for early and rapid rule out of Coronary Artery Disease Visit us at booth D500 Exhibition hall A2 Acarix AB’s (publ) (“Acarix”) ultra-sensitive acoustic CADScor®Syste...
2018 08 21
MAR | Interim Report, January – June 2018
MAR | Interim Report, January – June 2018 Acarix gains traction in key markets providing physicians and patients new opportunities ”Since the inception of Acarix, the company has been fully committed to developing a reliable, noninvasive and radiation-...
2018 05 23
MAR | Interim, Januari – March 2018
MAR | Interim, Januari – March 2018 CADScor®System launched in key markets “Acarix introduced the CADScor®System on the German, Swedish and Danish markets 11 months ago, in June 2017. The introduction was made without general reimbursement, which is...
2018 05 23
Acarix appoints senior cardiovascular medtech marketing expert as member of the Board of Directors
Acarix appoints senior cardiovascular medtech marketing expert as member of the Board of Directors Acarix, developer of the CADScor®System for Coronary Artery Disease (CAD) risk assessment, today announced the appointment of a highly experienced marketing...
2018 05 23
Acarix AB recruits Per Persson as Chief Commercial Officer
Acarix AB recruits Per Persson as Chief Commercial Officer Acarix AB (publ) (“Acarix”), today announced the recruitment of Per Persson as new Chief Commercial Officer. Acarix AB (publ) (“Acarix”), today announced the recruitment of Per Persson as new ...
2018 04 23
Notice of Annual General Meeting 2018
Notice of Annual General Meeting 2018 The shareholders of Acarix AB, reg. no. 559009-0667, (the ”Company”), are hereby convened to the annual general meeting to be held on Wednesday 23 May 2018, at 10.00 at Baker & McKenzie Advokatbyrå’s premises at Vasag...
2018 04 23
MAR | Annual report 2017
MAR | Annual report 2017 Today, Monday April 23, Acarix is publishing its Annual Report for 2017. For further information please contact:Christian Lindholm, Interim CEOE-mail: secli@acarix.comPhone: +46 705 118333 This information is information that...
2018 02 26
MAR | Year-end Report January-December 2017
MAR | Year-end Report January-December 2017 CADScor®System launched in key markets ”In 2017, we achieved historic milestones in Acarix – most noticeably the receipt of our first commercial order for CADScor®System in June and thus a confirmation of th...
2018 02 23
Medtech specialist Acarix AB names Christian Lindholm as Interim CEO
Medtech specialist Acarix AB names Christian Lindholm as Interim CEO Acarix AB (publ) (“Acarix”), developer of the CADScor®System for Coronary Artery Disease (CAD) risk assessment, today announced the appointment of the company’s current CFO, Christian Li...
2018 01 09
DAN-NICADII study to expand the applicability of the non-invasive Acarix CADScor®System for rapid ruling out Coronary Artery Disease
DAN-NICADII study to expand the applicability of the non-invasive Acarix CADScor®System for rapid ruling out Coronary Artery Disease Jan 09, 2018 Handheld system rules out coronary arterial stenosis, saving valuable time in frontline triage and avo...